Nanoelectroporation technology efficiently produces dual-targeted, nucleic acid-enriched extracellular vesicles (EVs) for disease treatment. This innovative method utilizes proprietary nano-electroporation to create EVs enriched with therapeutic nucleic acids, targeting peptides, and antibody conjugation. These EVs show excellent tissue targeting and penetration, delivering large amounts of nucleic acid drugs and escaping endosomes for efficient cellular uptake and utilization.

Nanoelectroporation outperforms conventional methods like BIO-RAD and Lonza＇s Nucleofector® by producing up to 50 times more extracellular vesicles (EVs) and over 1,000 times more mRNA loading. It uses focused electric pulses to minimize cell damage and ensure high transfection efficiency. Dual-targeting molecules (THP and hmAb) on EV surfaces enhance tissue specificity and cellular uptake. Nanoelectroporation is scalable and cost-effective, utilizing accessible materials to reduce costs.

Nanoelectroporation technology excels in gene therapy, EV therapy, regenerative medicine, and rare disease treatments by ensuring high transfection efficiency and precise gene delivery. It is also applicable in biopharmaceuticals, aiding in the development of advanced therapies and benefiting the academic and commercial sectors. It offers cost savings, reduces dependency on expensive components, and speeds up therapeutic development.